Thierry André Selected Research

Hypertension (High Blood Pressure)

1/2023	Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study.
1/2019	Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.
1/2019	Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first‑line therapy for metastatic colorectal cancer: GERCOR VELVET phase II study.
10/2016	Acute neurovascular events in cancer patients receiving anti-vascular endothelial growth factor agents: Clinical experience in Paris University Hospitals.
10/2013	[Regorafenib approved in Metastatic Colorectal cancer].
12/2012	Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thierry André Research Topics

Disease

112	Colorectal Neoplasms (Colorectal Cancer) 04/2024 - 09/2002
88	Neoplasms (Cancer) 03/2024 - 08/2002
50	Colonic Neoplasms (Colon Cancer) 04/2024 - 09/2002
34	Microsatellite Instability 03/2024 - 01/2004
24	Adenocarcinoma 03/2024 - 08/2002
15	Disease Progression 11/2023 - 03/2008
13	Neoplasm Metastasis (Metastasis) 10/2023 - 09/2002
10	Neutropenia 07/2023 - 01/2004
9	Pancreatic Neoplasms (Pancreatic Cancer) 03/2019 - 08/2002
7	Turcot syndrome 11/2023 - 02/2019
7	Stomach Neoplasms (Stomach Cancer) 01/2023 - 01/2003
6	Carcinoma (Carcinomatosis) 07/2023 - 01/2007
6	Hypertension (High Blood Pressure) 01/2023 - 12/2012
5	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022 - 08/2017
4	Fatigue 01/2023 - 01/2017
4	Hereditary Nonpolyposis Colorectal Neoplasms (Hereditary Nonpolyposis Colorectal Cancer) 01/2023 - 07/2019
4	Sarcoma (Soft Tissue Sarcoma) 12/2020 - 03/2012
3	Nausea 07/2023 - 01/2004
3	Mucositis 07/2023 - 01/2004
3	Alopecia (Baldness) 07/2023 - 01/2004
3	Asthenia 11/2015 - 01/2013
3	Breast Neoplasms (Breast Cancer) 06/2015 - 08/2002
3	Lung Neoplasms (Lung Cancer) 01/2012 - 08/2002
2	Rectal Neoplasms (Rectal Cancer) 03/2024 - 01/2019
2	Vomiting 07/2023 - 01/2004
2	Esophageal Neoplasms (Esophageal Cancer) 05/2023 - 01/2007
2	Peritoneal Neoplasms 01/2023 - 03/2016
2	Hand-Foot Syndrome 01/2023 - 10/2013
2	Chromosomal Instability (Chromosome Stability) 04/2022 - 07/2016
2	Lymphatic Metastasis 02/2022 - 11/2021
2	Frailty 01/2022 - 08/2007
2	Neuroendocrine Carcinoma 01/2020 - 10/2016
2	Diarrhea 01/2019 - 10/2013
2	Biliary Tract Neoplasms (Biliary Tract Cancer) 09/2016 - 07/2014
2	Exanthema (Rash) 11/2015 - 10/2013
2	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 03/2014 - 09/2002
1	Arthralgia (Joint Pain) 11/2023

Drug/Important Bio-Agent (IBA)

53	Fluorouracil (Carac)FDA LinkGeneric 07/2023 - 01/2003
51	Oxaliplatin (Eloxatin)FDA LinkGeneric 03/2024 - 08/2002
36	Leucovorin (Folinic Acid)FDA Link 07/2023 - 01/2003
34	Immune Checkpoint InhibitorsIBA 03/2024 - 03/2016
23	Irinotecan (Camptosar)FDA LinkGeneric 07/2023 - 06/2003
21	Bevacizumab (Avastin)FDA Link 01/2023 - 07/2006
17	Cetuximab (Erbitux)FDA Link 10/2023 - 01/2005
16	Biomarkers (Surrogate Marker)IBA 04/2022 - 05/2010
13	ErbB Receptors (EGF Receptor)IBA 01/2021 - 05/2005
13	Gemcitabine FDA Link 11/2020 - 08/2002
12	Cisplatin (Platino)FDA LinkGeneric 07/2023 - 01/2003
12	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019 - 01/2007
11	Monoclonal AntibodiesIBA 01/2019 - 01/2007
9	Capecitabine (Xeloda)FDA Link 01/2023 - 12/2006
8	NivolumabIBA 10/2023 - 01/2017
8	Docetaxel (Taxotere)FDA Link 07/2023 - 08/2002
8	Panitumumab (Vectibix)FDA Link 01/2021 - 11/2010
7	Sodium Glutamate (Accent)IBA 03/2024 - 05/2008
7	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 01/2008
6	IpilimumabIBA 10/2023 - 10/2018
6	PlatinumIBA 10/2023 - 08/2002
5	regorafenibIBA 01/2021 - 05/2013
5	Tyrosine Kinase InhibitorsIBA 01/2018 - 09/2002
4	pembrolizumabIBA 12/2023 - 01/2020
4	trifluridine tipiracil drug combinationIBA 01/2023 - 07/2018
4	Calcibiotic Root Canal SealerIBA 01/2020 - 01/2017
4	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2018 - 01/2012
4	XELOXIBA 03/2016 - 12/2012
3	Alanine Transaminase (SGPT)IBA 11/2023 - 01/2017
3	Trastuzumab (Herceptin)FDA Link 01/2023 - 04/2011
3	Circulating Tumor DNAIBA 10/2021 - 01/2020
3	Cell-Free Nucleic AcidsIBA 01/2021 - 01/2018
3	AntibodiesIBA 04/2019 - 01/2012
3	afliberceptIBA 01/2019 - 10/2013
3	130-nm albumin-bound paclitaxelIBA 01/2017 - 06/2015
3	Proteins (Proteins, Gene)FDA Link 07/2016 - 09/2012
2	avelumabIBA 10/2023 - 01/2021
2	human ERBB2 proteinIBA 04/2023 - 04/2011
2	tyramine-deoxysorbitolIBA 02/2022 - 11/2021
2	folfirinoxIBA 01/2021 - 01/2019
2	dabrafenibIBA 01/2020 - 01/2018
2	trametinibIBA 01/2020 - 01/2018
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2020 - 01/2018
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2020 - 03/2012
2	Carcinoembryonic AntigenIBA 01/2019 - 01/2003
2	Epidermal Growth Factor (EGF)IBA 01/2018 - 05/2013
2	Epirubicin (Ellence)FDA LinkGeneric 11/2014 - 01/2006
2	Imatinib Mesylate (Gleevec)FDA Link 03/2014 - 09/2002
2	Phosphotransferases (Kinase)IBA 10/2013 - 09/2002
2	Angiogenesis InhibitorsIBA 07/2007 - 12/2006
2	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 05/2004 - 05/2004
2	Hydroxyurea (Hydrea)FDA LinkGeneric 06/2003 - 01/2003
1	GlucocorticoidsIBA 04/2024
1	Prion ProteinsIBA 04/2024

Therapy/Procedure

66	Therapeutics 03/2024 - 09/2002
64	Drug Therapy (Chemotherapy) 03/2024 - 01/2004
29	Adjuvant Chemotherapy 03/2024 - 01/2004
11	Immunotherapy 05/2023 - 01/2017
6	Neoadjuvant Therapy 03/2024 - 04/2017
5	Chemoradiotherapy 05/2023 - 01/2007
2	Duration of Therapy 10/2021 - 01/2018
2	Aftercare (After-Treatment) 01/2017 - 01/2008
2	Induction Chemotherapy 05/2016 - 03/2008